Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “DHL”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableUnknownNCT02676414
What this trial is testing

Validation of a Hypertension Education Program

Who this might be right for
Arterial Hypertension
Charite University, Berlin, Germany 134
Not applicableStudy completedNCT06108037
What this trial is testing

DHL Survey on Generative AI for MyChart Messaging

Who this might be right for
Communication
Duke University 1,454
Early research (Phase 1)Study completedNCT01742988
What this trial is testing

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Who this might be right for
LymphomaRelapsed LymphomaRefractory Lymphoma+8 more
Curis, Inc. 106
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07552324
What this trial is testing

Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

Who this might be right for
DHLTHLDLBCL - Diffuse Large B Cell Lymphoma
Ruijin Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07638787
What this trial is testing

Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL

Who this might be right for
Large B-cell Lymphoma
Ruijin Hospital 40
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110